Designing ageing conditions in tumour microenvironment-A new possible modality for cancer treatment

Mechanisms of Ageing and Development

Volumn 130, Issue 1-2, 2009, Pages 76-85

  Leibovici, Judith ^a   Itzhaki, Orit ^a   Kaptzan, Tatiana ^a   Skutelsky, Ehud ^a   Sinai, Judith ^a   Michowitz, Moshe ^a   Asfur, Raida ^a   Siegal, Annette ^a   Huszar, Monica ^a   Schiby, Ginnette ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Age adjusted therapy; Ageing; Cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROCORTISONE; IMMUNOMODULATING AGENT; LEVAMISOLE;

AGE; AGED; AGING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL NEOPLASM; GROWTH INHIBITION; GROWTH RATE; IMMUNE RESPONSE; LYMPHOMA; MELANOMA B16; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR CELL; TUMOR CELL CULTURE; TUMOR GROWTH;

AGE FACTORS; AGING; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; LYMPHOMA; MELANOMA; MICE; MICE, INBRED AKR; MICE, INBRED C57BL; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SURVIVAL RATE;

MUS;

EID: 58149331694     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2008.03.004     Document Type: Article

References (82)

1. Anisimov V.N. Effect of host age on tumor growth rate in rodents. Front Biosci. 11 (2006) 412-422
2. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 14 (2007) 7-12
3. Balducci L., and Extermann M. Cancer and aging. An evolving panorama. Hematol. Oncol. Clin. North Am. 14 (2000) 1-16
4. Balducci L., and Lyman G.H. Cancer in the elderly. Epidemiologic and clinical implications. Clin. Geriatr. Med. 13 (1997) 1-14
5. Baumgart J., Zhukovskaya N.V., and Anisimov V.N. Carcinogenesis and aging.VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4 benzoquinone-guaninehydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats. Exp. Pathol. 33 (1988) 239-248
6. Bonafe M., Barbi C., Storci G., Salvioli S., Capri M., Olivieri F., Valensin S., Monti D., Gonos E.S., De Benedictis G., and Franceschi C. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Exp. Gerontol. 37 (2002) 1263-1271
7. Calabrese C.T., Adam Y.G., and Volk H. Geriatric colon cancer. Am. J. Surg. 125 (1973) 181-184
8. Callard R.E., Fazekas d.S.G., Basten A., and McKenzie I.F. Immune function in aged mice. V. Role of suppressor cells. J. Immunol. 124 (1980) 52-58
9. Cameron I.L. Cell proliferation and renewal in aging mice. J. Gerontol. 27 (1972) 162-172
10. Chahal H.S., and Drake W.M. The endocrine system and aging. J. Pathol. 211 (2007) 173-180
11. Cinamon U., Hier M.P., and Black M.J. Age as a prognostic factor for head and neck squamous cell carcinoma: should older patients be treated differently?. J. Otolaryngology 35 (2006) 8-12
12. Distelhorst C.W., and Dubyak G. Role of calcium in glucocorticosteroidinduced apoptosis of thymocytes and lymphoma cells: resurrection of old theories by new findings. Blood 91 (1998) 731-734
13. Donin N., Sinai J., Michowitz M., Hiss J., Nordenberg J., and Leibovici J. Role of immune response as determinant of tumour progression in function of host age in the B16 melanoma. Mech. Ageing Dev. 80 (1995) 121-137
14. Donin N., Sinai J., Staroselsky A., Mahlin T., Nordenberg J., and Leibovici J. Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice. Cancer Invest. 15 (1997) 416-421
15. Dunn P.L., and North R.J. Effect of advanced ageing on the ability of mice to cause tumour regression in response to immunotherapy. Immunology 74 (1991) 355-359
16. Dunn P.L., and North R.J. Effect of advanced aging on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cells. Cancer Immunol. Immunother. 33 (1991) 421-423
17. Dussault I., and Miller S.C. Effectiveness of immunotherapy in aged leukemic mice. Gerontology 41 (1995) 195-204
18. Ershler W.B. Why tumors grow more slowly in old people. J. Natl. Cancer Inst. 77 (1986) 837-839
19. Ershler W.B., Socinski M.A., and Green C.J. Bronchogenic cancer, metastasis, and aging. J. Am. Geriatr. Soc. 31 (1983) 673-676
20. Ershler W.B., Steward J.A., Hacker M.P., Moore A.L., and Tindle B.H. B16 murine melanoma and aging: slower growth and longer survival of mice. J. Natl. Cancer Inst. 72 (1984) 161-164
21. Facchini A., Mariani E., Mariani A.R., Papa S., Vitale M., and Manzoli F.A. Increased number of circulating Leu 11 (CD 16) large granular lymphocytes and decreased NK activity during human ageing. Clin. Exp. Immunol. 68 (1987) 340-347
22. Fisher C.J., Egan M.K., Smith P., Wicks K., Millis R.R., and Fentinan I.S. Histopathology of breast cancer in relation to age. Br. J. Cancer 75 (1997) 593-596
23. Franceschi C., Bonafe M., and Valensin S. Human Immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 18 (2000) 1717-1720
24. Garcia-Hernandez M.L., Hernandez-Pardo R., Garriglio P., and Berumen J. Interleukin-10 promotes B16 melanoma growth by inhibition of macrophage functions and induction of tumor and macrophage proliferation. Immunology 105 (2002) 231-243
25. Goldstein A.L., Schulof R.S., Naylor P.H., and Hall N.R. Thymosins and anti-thymosins: properties and clinical applications. Med. Oncol. Tumor Pharmacother. 3 (1986) 211-221
26. Gravekamp C. Cancer vaccines in old age. Exp. Gerontol. 42 (2007) 441-450
27. Gridelli C., and Hainsworth J. Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC. Lung Cancer 38 Suppl. 4 (2002) 37-41
28. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood 89 (1997) 1845-1853
29. Hayflick L. Ageing is not a disease. Ageing (Milano) 10 (1998) 146
30. Hirayama R., Hirokawa K., and Makinodan T. Change in the metastatic mode of B16 malignant melanoma in C57BL/6 mice with ageing and sex. IARC Sci. Publ. 58 (1985) 85-96
31. Ho S.P., Kramer K.E., and Ershler W.B. Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model. Cancer Immunol. Immunother. 3 (1990) 146-150
32. Holbrook N.J., and Ikeyama S. Age-related decline in cellular response to oxidative stress: links to growth factor signaling pathways with common defects. Biochem. Pharmacol. 64 (2002) 999-1005
33. Itzhaki O., Kaptzan T., Skutelsky E., Sinai J., Michowitz M., Siegal A., Schibi G., Huszar M., Ben-Dor L., and Leibovici J. Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged. Biochim. Biophys. Acta 1688 (2004) 145-159
34. Itzhaki O., Skutelsky E., Kaptzan T., Siegal A., Michowitz M., Sinai J., Huszar M., Nafar S., and Leibovici J. Macrophage-recognized molecules of apoptotic cells are expressed at higher levels in AKR lymphoma of aged as compared to young mice. Adv. Exp. Med. Biol. 479 (2000) 251-262
35. Itzhaki O., Skutelsky E., Kaptzan T., Siegal A., Sinai J., Schiby G., Michowitz M., Huszar M., and Leibovici J. Decreased DNA ploidy may constitute a mechanism of the reduced malignant behavior of B16 melanoma in aged mice. Exp. Gerontol. 43 (2008) 164-175
36. Itzhaki O., Skutelsky E., Kaptzan T., Sinai J., Michowitz M., Huszar M., and Leibovici J. Ageing-apoptosis relation in normal murine tissues. Mech. Ageing Dev. 124 (2003) 999-1012
37. Joudi F.N., Smith B.J., O'Donnell M.A., and Konety B.R. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J. Urol. 175 (2006) 1634-1640
38. Kaesberg P.R., and Ershler W.B. The importance of immunesenescence in the incidence and malignant properties of cancer in hosts of advanced age. J. Gerontol. 44 (1989) 63-66
39. Kaptzan T., Skutelsky E., Itzhaki O., Sinai J., Huszar M., Siegal A., Ben-Zvi R., Jossipov J., Yossipov Y., Michowitz M., Schiby G., and Leibovici J. Efficacy of anti-angiogenic treatment of tumours in old versus young mice. Mech. Ageing Dev. 127 (2006) 398-409
40. Kaptzan T., Skutelsky E., Itzhaki O., Sinai J., Michowitz M., Yossipov Y., Schiby G., and Leibovici J. Age-dependent differences in the efficacy of cancer immunotherapy in C57BL and AKR mouse strains. Exp. Gerontol. 39 (2004) 1035-1048
41. Kaptzan T., Skutelsky E., Michowitz M., Siegal A., Itzhaky O., Hoenig S., Hiss J., Kay S., and Leibovici J. Sensitivity to macrophages decreases with tumor progression in AKR lymphoma. Adv. Exp. Med. Biol. 479 (2000) 263-275
42. Katz E.B., and Boylan E.S. Stimulatory effect of high polyunsaturated fat diet on lung metastasis from the 13762 mammary adenocarcinoma in female retired breeder rats. J. Natl. Cancer Inst. 79 (1987) 351-358
43. Kawakami K., and Bloom E.T. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell. Mech. Ageing Dev. 41 (1987) 229-240
44. Klement H., St Croix B., Milsom C., May L., Guo Q., Yu J.L., Klement P., and Rak J. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am. J. Pathol. 171 (2007) 1342-1351
45. Kreisle R.A., Stebler B.A., and Ershler W.B. Effect of host age on tumor associated angiogenesis in mice. J. Natl. Cancer Inst. 82 (1990) 44-47
46. Kurtz J.E., and Dufour P. Strategies for improving quality of life in older patients with metastatic breast cancer. Drug Ageing 19 (2002) 605-622
47. Leibovici J., Susskind-Brudner G., and Wolman M. Direct antitumor effect of high-molecular-weight levan on Lewis lung carcinoma cells in mice. J. Natl. Cancer Inst. 65 (1980) 391-396
48. Lonardi S., Bortolami A., Stefani M., and Monfardini S. Oral anticancer drugs in the elderly: an overview. Drugs Ageing 24 (2007) 395-410
49. Makinodan T., and Kay M.M. Age influence on the immune system. Adv. Immunol. 29 (1980) 287-330
50. Mandelblatt J. Treating breast cancer: the age old dilemma of old age. J. Clin. Oncol. 24 (2006) 4369-4370
51. Mariani E., Monaco M.C., Cattini L., Sinoppi M., and Facchini A. Distribution and lytic activity of NK cell subsets in the elderly. Mech. Ageing Dev. 76 (1994) 177-187
52. Migliore L., and Coppede F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat. Res. 512 (2002) 135-153
53. Miller F.R., Aslakson C.J., and McEachern D. Modulation of host resistance to metastasis in the lungs of aged retired breeder mice. Invasion Metastasis 11 (1991) 233-240
54. Muskhelishvili L., Hart R.W., Turturro A., and James S.J. Age-related changes in the intrinsic rate of apoptosis in livers of diet-restricted and ad libitum fed B6C3F1 mice. Am. J. Pathol. 147 (1995) 20-24
55. Pawelec G., and Solana R. Immunosenescence. Immunol. Today 18 (1997) 514-516
56. Peto R., Roe F.J., Lee P.N., Levy N., and CLack J. Cancer and ageing in mice and men. Br. J. Cancer 32 (1975) 411-426
57. Pili R., Guo Y., Chang J., Nakanishi H., Martin G.R., and Passaniti A. Altered angiogenesis underlying age-dependent changes in tumor growth. J. Natl. Cancer Inst. 86 (1994) 1303-1314
58. Provinciali M., and Smorlesi A. Immunoprevention and immunotherapy of cancer in ageing. Cancer Immunol. Immunother. 54 (2005) 93-106
59. Provinciali M., Di Stefano G., and Fabris N. Evaluation of lymphokine-activated killer cell development in young and old healthy humans. Nat. Immunol. 14 (1995) 134-144
60. Provinciali M., Di Stefano G., Stronati S., and Fabris N. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients. Cytokine 10 (1998) 132-139
61. Ramesh H.S., Jain S., and Audisio R.A. Implications of aging in surgical oncology. Cancer J. 11 (2005) 488-494
62. Repetto L., and Balducci A. Case for geriatric oncology. Lancet Oncol. 3 (2002) 289-297
63. Rivard A., Fabre J.E., Silver M., Chen D., Murohara T., Kearney M., Magner M., Asahara T., and Isner J.M. Age-dependent impairment of angiogenesis. Circulation 99 (1999) 111-120
64. Rossi A., Colantuoni G., Maione P., Ferrara C., Airoma G., Barzelloni M.L., Castaldo V., and Gridelli C. Chemotherapy of breast cancer in the elderly. Curr. Med. Chem. 12 (2005) 297-310
65. Roth G.S. Hormone action during ageing: alterations and mechanisms. Mech. Ageing Dev. 9 (1979) 497-514
66. Sadoun E., and Reed M.J. Impaired angiogenesis and aging is associated with alterations in vessel density, matrix composition, inflammatory response and growth factor expression. J. Histochem. Cytochem. 51 (2003) 1119-1130
67. Sawhney R., Sehl M., and Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 11 (2005) 449-460
68. Schwab R., Walters C.A., and Weksler M.E. Host defense mechanisms and aging. Semin. Oncol. 16 (1989) 20-27
69. Shigemoto S., Kishimoto S., and Yamamura Y. Change of cell-mediated cytotoxicity with aging. J. Immunol. 115 (1975) 362-365
70. Simova J., Bubenik J., Voitenok N.N., and Gren E. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy. Folia Biol. (Praha) 35 (1989) 137-142
71. Siu L.L. Clinical trials in the elderly-a concept comes of age. N. Engl. J. Med. 356 (2007) 1575-1576
72. Smets L.A. Programmed cell death (apoptosis) and response to anticancer drugs. Anti-cancer Drugs 5 (1994) 3-9
73. Smets A., Salomons G., and van den Berg J. Glucocorticoid induced apoptosis in leukemia. Adv. Exp. Med. Biol. 457 (1999) 607-614
74. Solana R., Pawelec G., and Tarazona R. Aging and innate immunity. Immunity 24 (2006) 491-494
75. Strausser H.R., and Rosenstein M.M. Immunosuppression as a homeostatic mechanism in disease and aging. Adv. Exp. Med. Biol. 121B (1979) 277-281
76. Takeichi N., Li X.B., Hamada J., and Kobayashi H. Age-related decrease of pulmonary metastasis of rat mammary carcinoma by activated natural resistance. Cancer Immunol. Immunother. 31 (1990) 81-85
77. Takiguchi K., Inagawa H., Nishizawa T., Kohchi C., and Soma G. Perspectives for antitumor therapy based on the recognition mechanism by which macrophages identify undesirable foreign and native cells and molecules. Anticancer Res. 22 (2002) 4277-4280
78. Urban J.L., and Schreiber H. Rescue of the tumor-specific immune response of aged mice in vitro. J. Immunol. 133 (1984) 527-534
79. Wainfan E., Dizik M., Kilkenny M., and O'Callaghan J.P. Prolonged survival of female AKR mice fed diets supplemented with methionine and choline. Carcinogenesis 11 (1990) 361-363
80. Watanabe T. Suppressive effects of Lactobacillus casei cells, a bacterial immunostimulant, on the incidence of spontaneous thymic lymphoma in AKR mice. Cancer Immunol. Immunother. 42 (1996) 285-290
81. Yuhas J.M., and Ullrich R.L. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum. Cancer Res. 36 (1976) 161-166
82. Zang Y., and Herman B. Ageing and apoptosis. Mech. Ageing Dev. 123 (2002) 245-260